Impaired antimicrobial response and mucosal protection induced by ibuprofen in the immature human intestine
- 16 October 2018
- journal article
- research article
- Published by Springer Nature in Pediatric Research
- Vol. 84 (6) , 813-820
Abstract
The use of nonsteroidal anti-inflammatory drugs (NSAIDs) such as indomethacin (INDO) and ibuprofen (IBU) has been shown to be an effective therapy for the closure of patent ductus arteriosus (PDA). However, this treatment has been associated with an increased risk of developing enteropathies in neonates. Whether the use of IBU is safer than INDO for the immature intestine remains to be elucidated. The direct impact of IBU on the human immature intestinal transcriptome was investigated using serum-free organ culture. Differentially expressed genes were analyzed with Ingenuity Pathway Analysis software and compared with those previously reported with INDO. Validation of differentially expressed genes was confirmed by qPCR. We identified several biological processes that were significantly modulated by IBU at similar levels to what had previously been observed with INDO, while the expression of genes involved in “antimicrobial response” and “mucus production” was significantly decreased exclusively by IBU in the immature intestine. Our findings indicate that IBU has a harmful influence on the immature intestine. In addition to exerting many of the INDO observed deleterious effects, IBU alters pathways regulating microbial colonization and intestinal epithelial defense.Keywords
This publication has 34 references indexed in Scilit:
- The use of non-steroidal anti-inflammatory drugs for patent ductus arteriosus closure in preterm infantsSeminars in Fetal and Neonatal Medicine, 2017
- Recent Advances in Mitochondrial Aminoacyl-tRNA Synthetases and DiseaseTrends in Molecular Medicine, 2017
- The nitric oxide synthase 2 pathway is targeted by both pro- and anti-inflammatory treatments in the immature human intestineNitric Oxide, 2017
- Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infantsCochrane Database of Systematic Reviews, 2015
- The protective effect of trefoil factor 3 on the intestinal tight junction barrier is mediated by toll-like receptor 2 via a PI3K/Akt dependent mechanismBiochemical and Biophysical Research Communications, 2013
- Non-catalytic Regulation of Gene Expression by Aminoacyl-tRNA Synthetases2013
- Deleterious effects of indomethacin in the mid-gestation human intestineGenomics, 2013
- Neutrophil gelatinase-associated lipocalin (NGAL) in inflammatory bowel disease: association with pathophysiology of inflammation, established markers, and disease activityJournal of Gastroenterology, 2011
- The trefoil factor family – small peptides with multiple functionalitiesCellular and Molecular Life Sciences, 2008
- Activation of peroxisome proliferator-activated receptor isoforms and inhibition of prostaglandin H2 synthases by ibuprofen, naproxen, and indomethacin11Abbreviations: AA, arachidonic acid; ACO, acyl-CoA oxidase; COX; cyclooxygenase; NSAIDs, nonsteroidal anti-inflammatory drugs; PGHS, prostaglandin endoperoxide H synthase; PPP, platelet-poor plasma; PRP, platelet-rich plasma; PPAR, peroxisome proliferator-activated receptor; PPRE, peroxisome proliferator response element; and CoA coenzyme A.Biochemical Pharmacology, 2001